Argos Therapeutics (ARGS) 5.44 $ARGS Apple and

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 12:05 PM

Argos Therapeutics (ARGS) 5.44 $ARGS

Apple and Hanesbrands fall, LinkedIn and Symantec climb
AP - Mon Jun 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
ARGS: 5.44 (-0.16), LNKD: 190.01 (-0.44), EBIO: 2.18 (-0.11), DUK: 82.88 (+0.83), HBI: 25.59 (-0.88), AAPL: 94.05 (-2.05), SYMC: 20.75 (-0.49)

Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Positive outcome triggers the second tranche of the Company's previously announced financing agreement
ARGS: 5.44 (-0.16)

Argos Therapeutics to Participate in Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 08, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the Jefferies 2016 Healthcare Conference to be held June 7-10 at the Grand Hyatt in New York City.
ARGS: 5.44 (-0.16)

Earnings Estimates Moving Higher for Argos Therapeutics (ARGS): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:37AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 5.44 (-0.16)

Argos Therapeutics Reports First Quarter 2016 Financial Results and Operational Highlights
GlobeNewswire - Thu May 12, 3:05PM CDT
- Entered into Equity Financing for Up to $60 million -
ARGS: 5.44 (-0.16)

Argos Therapeutics to Host First Quarter 2016 Financial Results Conference Call on Thursday, May 12, 2016
GlobeNewswire - Thu May 05, 7:00AM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's first quarter 2016 financial results will be released after the market close on Thursday, May 12, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
ARGS: 5.44 (-0.16)

3 Buy-Ranked Healthcare Stocks Building Momentum Now
Zacks Premium Research - Zacks Investment Research - Mon Apr 25, 3:57PM CDT
These healthcare stocks have posted double digit share price gains over the last month, but we're talking about another kind of momentum that makes these corporations worth betting on.
ARGS: 5.44 (-0.16), INVA: 10.63 (-0.59), VTAE: 10.25 (-0.29), GSK: 41.12 (-1.44)

Insider Bets Paying Off At ARGS As New 52-Week High Reached
MarketNewsVideo.com - Wed Apr 13, 12:13PM CDT
In trading on Wednesday, shares of Argos Therapeutics Inc. touched a new 52-week high of $9.41/share.
ARGS: 5.44 (-0.16)

Surging Earnings Estimates Signal Good News for Argos Therapeutics (ARGS)
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:44AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Argos Therapeutics (ARGS) an interesting choice for the investors.
ARGS: 5.44 (-0.16)

Can The Uptrend Continue for Argos Therapeutics (ARGS)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 8:28AM CDT
Investors certainly have to be happy with Argos Therapeutics, Inc. (ARGS) and its short term performance
ARGS: 5.44 (-0.16)

Argos Therapeutics to Participate in 15th Annual Needham Healthcare Conference
GlobeNewswire - Thu Apr 07, 3:05PM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 15 Annual Needham Healthcare Conference to be held April 12-13 at the Westin New York Grand Central in New York City.
ARGS: 5.44 (-0.16)

The Last Time This Company Made A FDA Submission It Ran 2,100%-- Here's Why You Should Be Looking At It Right Now
ACCESSWIRE - Wed Mar 30, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT"

, an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval.
AGEN: 3.87 (-0.33), ARGS: 5.44 (-0.16)

CORRECTION -- Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 5:12PM CDT
In the release issued earlier today by Argos Therapeutics (Nasdaq:ARGS), please note that the "Selected Third Quarter 2015 Financial Results" header should be "Selected Fourth Quarter and Full-Year 2015 Financial Results." All other information in the press release remains the same.
ARGS: 5.44 (-0.16)

Argos Therapeutics reports 4Q loss
Automated Insights - Tue Mar 29, 3:59PM CDT
DURHAM, N.C. (AP) _ Argos Therapeutics Inc. (ARGS) on Tuesday reported a loss of $17.6 million in its fourth quarter.
ARGS: 5.44 (-0.16)

Argos Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results and Operational Highlights
GlobeNewswire - Tue Mar 29, 3:30PM CDT
- Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 in July 2015 -
ARGS: 5.44 (-0.16)

Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy
GlobeNewswire - Wed Mar 23, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis(R) technology platform, today announced the initiation of an investigator-sponsored Phase 2 clinical trial of AGS-003 in combination with standard platinum-doublet chemotherapy with or without radiation in patients with newly diagnosed Stage 3 non-small cell lung cancer (NSCLC).
ARGS: 5.44 (-0.16)

Argos Therapeutics to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call on Tuesday, March 29, 2016
GlobeNewswire - Tue Mar 22, 3:05PM CDT
Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies based on the Arcelis(R) technology platform, today announced that the Company's fourth quarter and full-year 2015 financial results will be released after the market closes on Tuesday, March 29, 2016. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.
ARGS: 5.44 (-0.16)

Argos Therapeutics to Participate in 6th Annual "Cancer Immunotherapy: A Long-Awaited Reality" Conference
GlobeNewswire - Tue Mar 22, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"

, an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the company will participate in the 6 Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference to be held on March 31, 2016 at the Apella Event Space Alexandria Center in New York City.
ARGS: 5.44 (-0.16)

Accenture (ACN) to Report Q2 Earnings: A Surprise in Store?
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 9:10AM CDT
Accenture plc (ACN) is set to report second-quarter fiscal 2016 results on Mar 24.
ARGS: 5.44 (-0.16), GME: 25.50 (-0.83), GIII: 44.18 (-1.05), ACN: 113.44 (-5.47)

Argos Therapeutics to Participate in Alliance for Regenerative Medicine Cell and Gene Therapy Investor Day
GlobeNewswire - Thu Mar 17, 7:00AM CDT
Argos Therapeutics, Inc. (Nasdaq:ARGS) ("Argos"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...